Intervention not reported
Adverse events · ethnic minority groups with type 2 diabetes mellitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · Patients with pain after surgical removal of lower wisdom teeth (third molars) requiring bone removal or with baseline moderate to severe…
1 finding from 1 review
The majority of adverse events were minor in nature and usually included nausea, vomiting, headaches and dizziness. Side effect profiles have not been included in a meta-analysis as multiple adverse events were…
7 studies
GRADE not reported
Any adverse events · advanced gastric and oesophago‐gastric junction adenocarcinoma
Biological therapy showed no clear difference in any adverse events compared with placebo, best supportive care (BSC) or no treatment (high certainty).
1 finding from 1 review
Any adverse events · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy probably leads to lower any adverse events compared with biological therapy (moderate certainty).
1 finding from 1 review
Any adverse events · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemmotherapy combined with biological therapy showed no clear difference in any adverse events compared with chemotherapy (moderate certainty).
1 finding from 1 review
Any adverse events · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy showed no clear difference in any adverse events compared with placebo, best supportive care (BSC) or no treatment (high certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and an intermediate or poor risk according to the International…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Serious adverse events · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the International Metastatic…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with resectable cholangiocarcinoma
It is very uncertain whether adjuvant chemotherapy changes serious adverse events compared with no chemotherapy (very low certainty).
1 finding from 1 review
Serious adverse events · people with resectable cholangiocarcinoma
1 finding from 1 review
Serious adverse events · patients with severe chronic rhinosinusitis with nasal polyps
It is very uncertain whether anti‐IL‐5 mAb (mepolizumab) changes serious adverse events compared with placebo (on top of topical steroids) (very low certainty).
1 finding from 1 review
Serious adverse events · patients with chronic rhinosinusitis with nasal polyps
It is very uncertain whether anti‐IgE mAb (omalizumab) changes serious adverse events compared with placebo (on top of topical steroids) (very low certainty).
1 finding from 1 review
Serious adverse events · patients with severe chronic rhinosinusitis with nasal polyps
Anti‐IL‐4Rα mAb (dupilumab) may leads to lower serious adverse events compared with placebo (on top of topical steroids) (low certainty).
1 finding from 1 review
Serious adverse events · people with hepatocellular carcinoma
1 finding from 1 review
Serious adverse events · people with hepatocellular carcinoma
It is very uncertain whether radioembolisation changes serious adverse events compared with chemoembolisation (very low certainty).
1 finding from 1 review
Serious adverse events · people with hepatocellular carcinoma
1 finding from 1 review
Serious adverse events · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy may leads to lower serious adverse events compared with biological therapy (low certainty).
1 finding from 1 review
Serious adverse events · advanced gastric and oesophago‐gastric junction adenocarcinoma
It is very uncertain whether chemmotherapy combined with biological therapy changes serious adverse events compared with chemotherapy (very low certainty).
1 finding from 1 review
Serious adverse events · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy probably leads to higher serious adverse events compared with placebo, best supportive care (BSC) or no treatment (moderate certainty).
1 finding from 1 review
Serious adverse events · advanced gastric and oesophago‐gastric junction adenocarcinoma
Biological therapy showed no clear difference in serious adverse events compared with placebo, best supportive care (BSC) or no treatment (low certainty).
1 finding from 1 review